Product is based on mesenchymal stem cells developed at the Roger Williams Medical Center.
NeoStem licensed the exclusive, worldwide rights to an autologous bone marrow-derived stem cell product to promote the healing of chronic wounds. This technology was developed by Vincent Falanga, M.D., chairman of the department of dermatology and skin surgery at Roger Williams Medical Center.
Primcel, a mesenchymal stem cell product, has pending patent applications. Development seeks to create a prepackaged product, ready for physician use in a clinical setting, consisting of three applications over a 12-week period.
In October 2008, the DoD appropriated $800,000 in funds for NeoStem to evaluate the potential use of adult stem cell therapy for treating wounds suffered by members of the U.S. military and first responders. “Our goal, through the DoD grant, is to determine if there are multiple sources of autologous stem cells to effectively treat wounds, and Dr. Falanga’s bone marrow procedure is an important step in that direction,” remarks Robin Smith, M.D., CEO of NeoStem. “Other procedures to be explored may use mobilized peripheral blood stem cells or VSELs (very small embryonic-like stem cells), for example.”
Related Stem Cell Deals
Pfizer Partners with University College London for Stem Cell-Based Therapies (Apr. 24, 2009)
iZumi Bio and Japanese Stem Cell Research Center to Collaborate (Apr. 14, 2009)
Stemgent Licenses TET’s Stem Cell Reprogramming Reagents (Feb. 11, 2009)
Novavax to Use Vivalis’ Duck Embryonic Stem Cell Line for Vaccine Production (Feb. 4, 2009)
PerkinElmer to Continue Cord Blood Stem Cell Partnership with M.D. Anderson (Jan. 16, 2009)